## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 18.2% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. Caution: momentum weakening (-1.5% MRS).

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($59.86)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Arrowhead Hits the Mark**
- Source: Los Angeles Business Journal | 20251208T170947 | Bullish | Relevance: 99%
- Pasadena-based Arrowhead Pharmaceuticals Inc. recently achieved its first FDA drug approval for Redemplo, a treatment for familial chylomicronemia syndrome (FCS), and received a $200 million milestone payment from Sarepta Therapeutics Inc. for a muscular dystrophy drug. These developments have significantly boosted Arrowhead's stock, which saw a 550% increase since April. The company aims to broaden Redemplo's applications and continues developing 20 other drugs in its pipeline.

**2. Arrowhead Pharmaceuticals stock soars after dosing first subjects in trial**
- Source: Investing.com | 20251208T170948 | Bullish | Relevance: 98%
-  Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) stock surged 14.7% after announcing it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT. This investigational RNAi therapeutic targets tauopathies, including Alzheimer’s disease, using a novel delivery system designed to cross the blood-brain barrier. Initial data from the study is anticipated in the second half of 2026.

**3. Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies**
- Source: Business Wire | 20251208T120947 | Bullish | Relevance: 97%
- Arrowhead Pharmaceuticals has initiated a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference (RNAi) therapeutic targeting Alzheimer's disease and other tauopathies. ARO-MAPT leverages the TRiM™ platform for subcutaneous administration and CNS delivery, aiming to prevent or reverse tau protein accumulation. Early findings from preclinical studies support potent and long-lasting tau suppression, with initial clinical data expected in the second half of 2026.

**4. Arrowhead Pharmaceuticals Flourishes with Key Milestones and Growth Projections**
- Source: StocksToTrade | 20251208T171400 | Bullish | Relevance: 97%
- Arrowhead Pharmaceuticals (NASDAQ: ARWR) has seen a significant stock surge, driven by promising clinical trial results, FDA Breakthrough Therapy designation for plozasiran, and a $200M milestone payment from Sarepta. The company reported a striking revenue increase to $829.4M in fiscal year-end 2025, reversing prior losses and strengthening its financial position. These developments, along with strategic collaborations, position Arrowhead for continued growth and market expansion in the biotech sector.

**5. Norges Bank Invests $30.41 Million in Arrowhead Pharmaceuticals, Inc. $ARWR**
- Source: MarketBeat | 20251208T110948 | Somewhat-Bullish | Relevance: 97%
- Norges Bank recently acquired a new stake of 1,924,957 shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), totaling approximately $30.41 million. Other institutional investors like Vanguard Group Inc. and UBS AM also increased their holdings in the biotechnology company. Analysts have issued a "Moderate Buy" rating for ARWR with an average price target of $53.33, while insiders have sold a significant number of shares recently.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |
| 2025-12-01 | B of A Securiti | $62 | $42 | +48% |
| 2025-12-01 | Chardan Capital | $60 | $60 | 0% |
| 2025-11-26 | Morgan Stanley | $48 | $45 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | HC Wainwright & | main | Buy |
| 2025-12-01 | B of A Securiti | main | Buy |
| 2025-12-01 | Chardan Capital | main | Buy |
| 2025-11-26 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($1.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Elevated short interest (11.1%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 7 raises (avg +38%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -30% YoY, concerning. Analyst sentiment positive (7 raises, avg +38%). Insider selling cluster ($1.6M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.5B |
| Beta | 1.29 |
| 52W Range | $9.57 - $71.50 |
| Short Interest | 11.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 19.7% to 18.2% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Extended beyond STRENGTH zone (18.2% > 6.0%), caution on chasing. MRS_5 at 7.8% confirms short-term momentum alignment. Outperforming sector by 21.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.09), confirming momentum. RSI overbought at 76, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 18.22% (CS: 100) | Strong |
| RSI_14 | 75.9 | Overbought |
| MACD Histogram | 2.09 | Bullish |
| vs SMA20 | 1.402x | Above |
| vs SMA50 | 1.624x | Above |
| vs SMA200 | 2.883x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $68.60
- **Stop Loss:** $59.86 (12.7% risk)
- **Target:** $77.34 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 57
- **Position Value:** $3,910.20
- **Portfolio %:** 3.91%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*